These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6102523)

  • 21. Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system.
    Shen YT; Pittman TJ; Buie PS; Bolduc DL; Kane SA; Koblan KS; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 2001 Aug; 298(2):551-8. PubMed ID: 11454916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of bucindolol on neurohormonal activation in congestive heart failure.
    Eichhorn EJ; McGhie AL; Bedotto JB; Corbett JR; Malloy CR; Hatfield BA; Deitchman D; Willard JE; Grayburn PA
    Am J Cardiol; 1991 Jan; 67(1):67-73. PubMed ID: 1670902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potent new beta2-adrenoceptor blocking agent.
    Imbs JL; Miesch F; Schwartz J; Velly J; Leclerc G; Mann A; Wermuth CG
    Br J Pharmacol; 1977 Jul; 60(3):357-62. PubMed ID: 19116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [On the cardiovascular and beta-adrenergic blocking effects produced in the beagle dog by repeated oral administration of talinolol (Cordanum) and propranolol (author's transl)].
    Heer S; Femmer K
    Pharmazie; 1980; 34(5-6):317-20. PubMed ID: 6106208
    [No Abstract]   [Full Text] [Related]  

  • 25. Vasodilating beta-adrenoceptor blocking drugs do not redistribute myocardial flow during acute coronary ligation in dogs.
    Berdeaux A; Bonhenry C; Giudicelli JF
    Eur J Pharmacol; 1985 Jun; 112(3):379-85. PubMed ID: 2862054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation.
    Hollenberg NK; Adams DF; McKinstry DN; Williams GH; Borucki LJ; Sullivan JM
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):219S-225S. PubMed ID: 37877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular actions of a new metabolite of propranolol: isopropylamine.
    Ishizaki T; Privitera PJ; Walle T; Gaffney TE
    J Pharmacol Exp Ther; 1974 Jun; 189(3):626-32. PubMed ID: 4152314
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of carotid occlusion of pulmonary vascular resistance in anesthetized dogs.
    Pace JB
    Proc Soc Exp Biol Med; 1978 Jun; 158(2):215-9. PubMed ID: 27819
    [No Abstract]   [Full Text] [Related]  

  • 29. Downregulation of propranolol-sensitive beta-adrenoceptor signaling after inhibition of nitric oxide synthesis.
    Whalen EJ; Bates JN; Johnson AK; Lewis SJ
    Br J Pharmacol; 2006 Apr; 147(7):755-64. PubMed ID: 16474417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers.
    O'Connor PC; Finch MJ; Harron DW; Meredith PA; McDevitt DG; Shanks RG
    Br J Clin Pharmacol; 1985 Dec; 20(6):659-67. PubMed ID: 2868744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of cardioselective versus noncardioselective beta blockade on subendocardial blood flow and contractile function in ischemic myocardium.
    Buck JD; Gross GJ; Warltier DC; Jolly SR; Hardman HF
    Am J Cardiol; 1979 Oct; 44(4):657-63. PubMed ID: 39449
    [No Abstract]   [Full Text] [Related]  

  • 32. [Changes in regional hemodynamics in response to blocking of the adrenergic beta receptors].
    Granata L; Caraffa Braga E; Cevese A; Data PG
    Boll Soc Ital Biol Sper; 1970 Feb; 46(4):170-3. PubMed ID: 4396928
    [No Abstract]   [Full Text] [Related]  

  • 33. On the clinical pharmacology of talinolol, a new beta 1-adrenoceptor blocking agent.
    Haustein KO; Fiehring H; Oltmanns G; Femmer K
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):465-70. PubMed ID: 43294
    [No Abstract]   [Full Text] [Related]  

  • 34. Haemodynamic and coronary vascular responses after beta-adrenoceptor blockade in the anaesthetised dog: a comparison of tolamolol with practolol and propranolol.
    Adam KR; Boyles SM
    Eur J Pharmacol; 1974 Apr; 26(1):96-107. PubMed ID: 4151643
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular effects of 5-hydroxypropranolol (ORF 12592) in dogs.
    Ram N; Bauer EW; Hesse UC; Heilman RD
    Arch Int Pharmacodyn Ther; 1977 Jul; 228(1):118-25. PubMed ID: 921395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs.
    Pelat M; Verwaerde P; Galitzky J; Lafontan M; Berlan M; Senard JM; Montastruc JL
    J Pharmacol Exp Ther; 2003 Jan; 304(1):246-53. PubMed ID: 12490598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs.
    Uchida W; Shibasaki K; Matsuda Y; Asano M; Takenaka T
    J Cardiovasc Pharmacol; 1993 Aug; 22(2):247-52. PubMed ID: 7692165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular and beta-adrenergic blocking effects of timolol.
    Mouillé P; Schmitt H; Cheymol G; Gauter E
    Eur J Pharmacol; 1976 Feb; 35(2):235-43. PubMed ID: 2481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of timolol in the unanesthetized pregnancy ewe and fetus.
    Van Petten GR
    Proc West Pharmacol Soc; 1980; 23():191-5. PubMed ID: 7403126
    [No Abstract]   [Full Text] [Related]  

  • 40. Involvement of beta 2-adrenoceptor-mediated mechanisms in the cardiovascular responses to alpha 1- and alpha 2-adrenoceptor antagonism in conscious, unrestrained, Long Evans and Brattleboro rats.
    Gardiner SM; Bennett T
    Br J Pharmacol; 1988 Jan; 93(1):9-22. PubMed ID: 2894880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.